信迪利单抗联合培美曲塞和铂类一线治疗非鳞NSCLC的3期研究
这项随机双盲3期研究纳入397例未经治疗、无EGFR/ALK敏感突变的局部晚期或转移性非鳞NSCLC患者,按2:1随机接受信迪利单抗或安慰剂联合培美曲塞和铂类治疗。截至2019年11月15日,中位随访8.9个月,信迪利单抗组中位PFS显著长于安慰剂组(8.9 vs 5.0个月;HR 0.482,95%CI 0.362-0.643;p<0.00001),确认ORR分别为51.9%和29.8%,≥3级不良事件发生率分别为61.7%和58.8%。
要点
- 信迪利单抗联合化疗较安慰剂联合化疗显著延长中位PFS(8.9 vs 5.0个月)。
- 确认ORR在信迪利单抗组为51.9%,安慰剂组为29.8%。
- ≥3级不良事件发生率两组相近(61.7% vs 58.8%)。
核心结论
- 在未经治疗的中国局部晚期或转移性非鳞NSCLC患者中,信迪利单抗联合培美曲塞和铂类较单纯化疗显著延长PFS,安全性可控。
研究设计与样本
- 随机、双盲、3期研究,纳入397例未经治疗、无EGFR/ALK敏感突变的局部晚期或转移性非鳞NSCLC患者,按2:1随机接受信迪利单抗200 mg或安慰剂联合培美曲塞和铂类每3周一次共4周期,后续信迪利单抗或安慰剂联合培美曲塞维持治疗。
- 主要终点为独立影像学评审委员会判定的PFS。
主要发现
- 截至2019年11月15日,中位随访8.9个月,信迪利单抗联合组中位PFS为8.9个月,安慰剂联合组为5.0个月(HR 0.482,95%CI 0.362-0.643;p<0.00001)。
- 确认ORR在信迪利单抗联合组为51.9%(95%CI 45.7%-58.0%),安慰剂联合组为29.8%(95%CI 22.1%-38.4%)。
- ≥3级不良事件发生率在信迪利单抗联合组为61.7%,安慰剂联合组为58.8%。
关键数值与推荐
- 信迪利单抗联合组中位PFS 8.9个月 vs 安慰剂联合组5.0个月,HR 0.482(95%CI 0.362-0.643),p<0.00001。
- 确认ORR:信迪利单抗联合组51.9%(95%CI 45.7%-58.0%),安慰剂联合组29.8%(95%CI 22.1%-38.4%)。
- ≥3级不良事件发生率:信迪利单抗联合组61.7%,安慰剂联合组58.8%。
临床怎么用
- 对于未经治疗、无EGFR/ALK敏感突变的局部晚期或转移性非鳞NSCLC中国患者,可考虑信迪利单抗联合培美曲塞和铂类作为一线治疗选择。
- 治疗期间需关注不良事件,≥3级不良事件发生率与单纯化疗相近。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Sintilimab, an anti-programmed death 1 antibody, plus pemetrexed and platinum had revealed promising efficacy for nonsquamous NSCLC in a phase 1b study. We conducted a randomized, double-blind, phase 3 study to compare the efficacy and safety of sintilimab with placebo, both in combination with such chemotherapy (ClinicalTrials.gov: NCT03607539). METHODS: A total of 397 patients with previously untreated, locally advanced or metastatic nonsquamous NSCLC without sensitizing EGFR or anaplastic lymphoma kinase genomic aberration were randomized (2:1 ratio) to receive either sintilimab 200 mg or placebo plus pemetrexed and platinum once every 3 weeks for four cycles, followed by sintilimab or placebo plus pemetrexed therapy. Crossover or treatment beyond disease progression was allowed. The primary end point was progression-free survival (PFS) as judged by an independent radiographic review committee. RESULTS: As of November 15, 2019, the median follow-up was 8.9 months. The median PFS was significantly longer in the sintilimab-combination group than that in the placebo-combination group (8.9 versus 5.0 mo; hazard ratio, 0.482, 95% confidence interval [CI]: 0.362-0.643; p < 0.00001). The confirmed objective response rate was 51.9% (95% CI: 45.7%-58.0%) in the sintilimab-combination group and 29.8% (95% CI: 22.1%-38.4%) in placebo-combination group. The incidence of grade 3 or higher adverse events was 61.7% in sintilimab-combination group and 58.8% in placebo-combination group. CONCLUSIONS: In Chinese patients with previously untreated, locally advanced or metastatic nonsquamous NSCLC, the addition of sintilimab to chemotherapy with pemetrexed and platinum resulted in considerably longer PFS than with chemotherapy alone with manageable safety profiles.
引用
- Yang Y, Wang Z, Fang J, et al. Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11). J Thorac Oncol. 2020. PMID: 32781263. doi:10.1016/j.jtho.2020.07.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。